Cargando…
Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care
BACKGROUND: Previous experiences with non-medical switching of adalimumab (ADA) in patients with chronic inflammatory rheumatic diseases (CIRD) come mainly from phase III extension of randomised clinical trials and little from routine care. OBJECTIVES: To analyse treatment trajectories over 2 years...
Autores principales: | Redeker, Imke, Moustakis, Stefan, Tsiami, Styliani, Baraliakos, Xenofon, Andreica, Ioana, Buehring, Bjoern, Braun, Jürgen, Kiltz, Uta |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
SAGE Publications
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10492472/ https://www.ncbi.nlm.nih.gov/pubmed/37694183 http://dx.doi.org/10.1177/1759720X231197087 |
Ejemplares similares
-
Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021) -
Effectiveness and safety of a biosimilar-to-biosimilar switch of the
TNF inhibitor etanercept in patients with chronic inflammatory rheumatic
diseases
por: Kiltz, Uta, et al.
Publicado: (2022) -
Facilitators and barriers for vaccination in patients with inflammatory rheumatic musculoskeletal diseases: a prospective cohort study
por: Andreica, Ioana, et al.
Publicado: (2023) -
SARS-CoV-2 vaccination willingness and predictors in patients with chronic inflammatory rheumatic diseases (CIRD) and without CIRD
por: Roman, Iulia, et al.
Publicado: (2022) -
Facilitators and barriers of vaccine uptake in patients with autoimune inflammatory rheumatic disease: a scoping review
por: Neusser, Silke, et al.
Publicado: (2022)